Anti-inflammatory action of geniposide promotes wound healing in diabetic rats

• Published in: Pharmaceutical biology Vol. 60; no. 1; pp. 294 - 299
• Main Authors: Chen, Xiao-yan, Jiang, Wen-wen, Liu, Yan-ling, Ma, Zhao-xia, Dai, Jian-qiang
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2022; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Administration, Oral; Animal models; Animals; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - isolation & purification; Anti-Inflammatory Agents - pharmacology; Antibacterial activity; Blood Glucose - drug effects; Cytokines - metabolism; Diabetes; Diabetes mellitus; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - drug therapy; Diabetic skin lesion; Dose-Response Relationship, Drug; fasting plasma glucose; Fibroblasts; Gardenia - chemistry; glycated haemoglobin; IL-1β; Inflammation; Interleukin 10; Interleukin 6; Iridoids - administration & dosage; Iridoids - isolation & purification; Iridoids - pharmacology; Lesions; Male; Metastases; Oral administration; Platelet aggregation; Rats; Rats, Wistar; Streptozocin; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Tumors; Wound healing; Wound Healing - drug effects; fasting plasma glucose; glycated haemoglobin; interleukin-10; Diabetic skin lesion
• ISSN: 1388-0209; 1744-5116
• DOI: 10.1080/13880209.2022.2030760

As a major active iridoid glycoside from Gardenia jasminoides J. Ellis (Rubiaceae), geniposide possesses various pharmacological activities, including anti-platelet aggregation and anti-inflammatory action. This study explores the effect of geniposide in diabetic wound model by anti-inflammatory action. Diabetic rodent model in Wistar rats was induced by streptozotocin combined with high-fat feed. The selected rats were divided into control group, the diabetic model group and geniposide subgroups (200, 400 and 500 mg/kg), and orally administrated once daily with saline or geniposide. Wound area and histochemical indicators were measured on day 7 after continuous administration, to assess lesion retraction, inflammatory cells and fibroblasts. Geniposide notably enhanced lesion retraction by 1.06-1.84 times on day 7 after surgical onset in diabetic rats (p < 0.05). In the pathological experiment by HE staining, geniposide significantly reduced inflammatory cell infiltration and proliferation of fibroblasts in the central lesion regions. In diabetic rats treated with geniposide, the levels of pro-inflammatory factors (tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β)) and IL-6 were significantly reduced (p < 0.05), followed with the increment of IL-10 in a dose-dependent manner. The IC 50 of geniposide on TNF-α, IL-1β and IL-6 could be calculated as 1.36, 1.02 and 1.23 g/kg, respectively. It assumed that geniposide-induced IL-10 expression contributed to inhibiting the expression of pro-inflammatory factors. Geniposide promoted diabetic wound healing by anti-inflammation and adjusting blood glucose. Further topical studies are required to evaluate effects on antibacterial activity and skin regeneration.